Wall Street brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to post sales of $3.96 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Crispr Therapeutics' earnings, with estimates ranging from $250,000.00 to $14.80 million. Crispr Therapeutics posted sales of $211.93 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 98.1%. The company is scheduled to report its next earnings report on Monday, October 26th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $7.19 million for the current financial year, with estimates ranging from $200,000.00 to $29.90 million. For the next fiscal year, analysts anticipate that the firm will report sales of $38.67 million, with estimates ranging from $3.50 million to $90.00 million. Zacks Investment Research's sales calculations are an average based on a survey of sell-side research analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, July 27th. The company reported ($1.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.95) by ($0.35). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $19.77 million. Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The company's revenue for the quarter was down 86.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.01) earnings per share.

Several equities research analysts have recently commented on the company. Bank of America assumed coverage on Crispr Therapeutics in a report on Monday, October 5th. They set a "buy" rating and a $110.00 price objective for the company. BofA Securities assumed coverage on Crispr Therapeutics in a report on Monday, October 5th. They set a "buy" rating and a $110.00 price objective for the company. ValuEngine upgraded Crispr Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, October 1st. BidaskClub upgraded Crispr Therapeutics from a "hold" rating to a "buy" rating in a report on Wednesday, September 2nd. Finally, Citigroup restated a "sell" rating on shares of Crispr Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of "Buy" and a consensus price target of $93.31.

In other Crispr Therapeutics news, President Rodger Novak sold 25,000 shares of the business's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $92.62, for a total value of $2,315,500.00. Following the transaction, the president now owns 651,940 shares of the company's stock, valued at $60,382,682.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael John Tomsicek sold 12,000 shares of the business's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $92.26, for a total value of $1,107,120.00. Following the completion of the transaction, the chief financial officer now directly owns 12,410 shares in the company, valued at approximately $1,144,946.60. The disclosure for this sale can be found here. In the last three months, insiders sold 133,000 shares of company stock worth $12,064,743. Insiders own 21.40% of the company's stock.

A number of hedge funds have recently bought and sold shares of the business. Sandy Spring Bank lifted its position in shares of Crispr Therapeutics by 13.0% during the 2nd quarter. Sandy Spring Bank now owns 1,053 shares of the company's stock valued at $77,000 after buying an additional 121 shares during the last quarter. Slow Capital Inc. lifted its position in shares of Crispr Therapeutics by 1.0% during the 2nd quarter. Slow Capital Inc. now owns 13,043 shares of the company's stock valued at $959,000 after buying an additional 130 shares during the last quarter. Flagship Harbor Advisors LLC lifted its position in shares of Crispr Therapeutics by 4.2% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 3,700 shares of the company's stock valued at $271,000 after buying an additional 150 shares during the last quarter. WASHINGTON TRUST Co lifted its position in shares of Crispr Therapeutics by 81.9% during the 2nd quarter. WASHINGTON TRUST Co now owns 473 shares of the company's stock valued at $35,000 after buying an additional 213 shares during the last quarter. Finally, Advisor Group Holdings Inc. lifted its position in shares of Crispr Therapeutics by 1.2% during the 2nd quarter. Advisor Group Holdings Inc. now owns 19,399 shares of the company's stock valued at $1,425,000 after buying an additional 222 shares during the last quarter. 55.29% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ CRSP opened at $109.83 on Monday. The company has a market cap of $7.71 billion, a price-to-earnings ratio of 238.76 and a beta of 2.31. Crispr Therapeutics has a 52 week low of $32.30 and a 52 week high of $111.90. The business has a 50 day moving average price of $87.55 and a 200-day moving average price of $73.85.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What does a dividend yield signify to investors?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

20 "Past Their Prime" Stocks to Dump From Your Portfolio

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.

We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

View the "20 "Past Their Prime" Stocks to Dump From Your Portfolio".



Source link